Arginase inhibitor is disclosed, characteristic is treated or diagnosed with what and is the illness of the high arginase activities of exception in mammal or abnormal low nitric oxide levels, including gives the present composition to mammal. The present invention includes the composition comprising alpha-amino acid compound or derivatives thereof or its salt, wherein the first substituent group and the second substituent group are connected to α-carbon of the compound. First substituent group includes the component part selected from boric acid and N- hydroxyl guanidine. Second substituent group includes proximal end nitrogen-atoms,Wherein the proximal end nitrogen is alkali,Further wherein proximal end nitrogen by two,The chain of three or four carbon is separated with the α-carbon,Condition be the compound be not 2- amino-6,7-dihydroxy boryl -2- (3- (piperazine -1- base) propyl) caproic acid,2- (3- (4- acetylpiperazine -1- base) propyl) -2- amino-6,7-dihydroxy boryl caproic acid,2- amino-6,7-dihydroxy boryl -2- (3- (4- (4- cyanobenzoyl) piperazine -1- base) propyl caproic acid or 2- amino-6,7-dihydroxy boryl -2- (3- (4- (3- methoxybenzene aminocarbonyl) piperazine -1- base) propyl) caproic acid.公開了精氨酸酶抑制劑，其用於治療或診斷特徵爲哺乳動物中的異常高的精氨酸酶活性或異常低的氧化氮水平的病症，包括將本發明組合物給予哺乳動物。本發明包括包含α‑氨基酸化合物或其衍生物或其鹽的組合物，其中第一取代基和第二取代基連接至該化合物的α‑碳。第一取代基包括選自硼酸和N‑羥基胍的組成部分。第二取代基包括近端氮原子，其中所述近端氮是鹼性的，進一步地其中近端氮通過兩個、三個或四個碳的鏈與所述α‑碳分開，條件是所述化合物不是2‑氨基‑6‑二羥硼基‑2‑(3‑(哌嗪‑1‑基)丙基)己酸、2‑(3‑(4‑乙酰哌嗪‑1‑基)丙基)‑2‑氨基‑6‑二羥硼基己酸、2‑氨基‑6‑二羥硼基‑2‑(3‑(4‑(4‑氰基苯甲酰基)哌嗪‑1‑基)丙基己酸或2‑氨基‑6‑二羥硼基‑2‑(3‑(4‑(3‑甲氧基苯氨羰基)哌嗪‑1‑基)丙基)己酸。
